Crisaborole and Apremilast: PDE4 Inhibitors with Similar Mechanism of Action, Different Indications for Management of Inflammatory Skin Conditions

• 作者: Jan M. Kitzen Joseph V. Pergolizzi Jr. Robert B. Raffa Robert Taylor Jr.
• 来源期刊: 药理与制药(英文)
• 学科: 医学
• 关键词: Crisaborole Apremilast PHOSPHODIESTERASE PDE4 Inflammation CYTOKINES INTERLEUKINS cAMP
• 年，卷（期）: 2018,（9）
• 页码范围: 357-381
• 页数: 25页
• 分类号: R73

摘要

Two selective phosphodiesterase-4 (PDE4) inhibitors—viz., crisaborole (Eucrisa®, Pfizer) and apremilast (Otezla®, Celgene)—have recently received approval by the United States Food and Drug Administration for the treatment of related but different dermatologic skin conditions (viz., atopic dermatitis and plaque psoriasis, respectively). The purpose of this review is to summarize the underlying biochemistry and pathophysiology associated with these dermatologic conditions, review the chemistry, pharmacology and safety of each of these products, and present preclinical and clinical evidence that may help explain why these two PDE4 inhibitors offer new treatment options for these skin conditions.